Zogenix (NASDAQ:ZGNX) and Prothena (NASDAQ:PRTA) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, profitability, analyst recommendations and institutional ownership.
Volatility & Risk
Zogenix has a beta of 1.92, meaning that its stock price is 92% more volatile than the S&P 500. Comparatively, Prothena has a beta of 2.26, meaning that its stock price is 126% more volatile than the S&P 500.
This table compares Zogenix and Prothena’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Zogenix||$9.82 million||220.07||-$123.91 million||($3.23)||-15.73|
Zogenix has higher revenue and earnings than Prothena. Zogenix is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
99.7% of Prothena shares are held by institutional investors. 4.4% of Zogenix shares are held by company insiders. Comparatively, 4.4% of Prothena shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
This is a breakdown of current ratings and price targets for Zogenix and Prothena, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Zogenix presently has a consensus target price of $65.30, indicating a potential upside of 28.54%. Prothena has a consensus target price of $11.39, indicating a potential upside of 44.30%. Given Prothena’s higher probable upside, analysts plainly believe Prothena is more favorable than Zogenix.
This table compares Zogenix and Prothena’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Zogenix beats Prothena on 7 of the 13 factors compared between the two stocks.
Zogenix, Inc., a pharmaceutical company, develops and commercializes therapies for the treatment of transformative central nervous system disorders in the United States. Its lead product candidate is the Fintepla/ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was founded in 2006 and is headquartered in Emeryville, California.
Prothena Corporation plc, a clinical-stage neuroscience company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, a antibody that is in Phase I clinical trial for the treatment of ATTR amyloidosis. Its discovery-stage programs include Tau for treating Alzheimer's disease, progressive supranuclear palsy, frontotemporal dementia, chronic traumatic encephalopathy, and other tauopathies; Aß, or Amyloid Beta, a protein for the treatment of Alzheimer's disease; TDP-43 for amyotrophic lateral sclerosis and frontotemporal dementia; and other products for neurodegeneration. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Celgene Corporation to develop antibodies. Prothena Corporation plc was founded in 2012 and is based in Dublin, Ireland.
Receive News & Ratings for Zogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix and related companies with MarketBeat.com's FREE daily email newsletter.